Awakn Life Sciences Inc.

Recent News

  • Awakn Life Sciences to Participate in the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

    Toronto, Ontario--(Newsfile Corp. - June 10, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, and Professor Celia Morgan, Head of Awakn's Ketamine-Assisted Psychotherapy for Addiction Practice, will participate in H.C. Wainwright's Psychedelics in Psychiatry and Beyond Virtual Conference panels on Thursday, June 17, 2021. H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual ConferenceDate: Thursday, June 17thTime: 9:00 -...

    2021-06-10 8:00 AM EDT
  • Awakn Life Sciences Initiates New Chemical Entity Development Program with Evotec as Research Partner and Addiction Expert, Prof. David Nutt, as Program Lead

    Toronto, Ontario--(Newsfile Corp. - April 27, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicines to treat Addiction, announced today the initiation of a new chemical entity (NCE) development program to strengthen Awakn's pipeline for the treatment of a broad range of addictions. The Company has also announced the appointment of Evotec as NCE research partner and the selection of Prof. David Nutt, one of the world's leading experts on...

    2021-04-27 7:30 AM EDT
  • Awakn Life Sciences Inc. Announces Two Key Appointments to Its Board of Directors

    Toronto, Ontario--(Newsfile Corp. - April 19, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat addiction, announced today the appointment of Stephen Page and Professor John Papastergiou as independent non-executive directors to the Company's Board of Directors. Adding significant pharmaceutical and healthcare sector experience and independent board governance to Awakn.Stephen Page has worked in executive and Board of Director roles in the UK healthcare industry for over...

    2021-04-19 9:17 AM EDT
  • Awakn Launches Digital Unit and Signs Agreement with the University of Exeter to Improve Addiction Treatment Through Artificial Intelligence and Big Data

    London, United Kingdom--(Newsfile Corp. - April 12, 2021) - Awakn Life Sciences Inc., a clinical-biotech company researching, developing, and delivering psychedelic medicine to treat addiction and other mental health conditions, today launched 'Awakn Digital', a new unit focused on using advanced analytics to improve the effectiveness of Psychedelic-Assisted Psychotherapy in treating Addiction. Awakn deepened its partnership with the University of Exeter to apply the latest developments in digital, technology and innovation in healthcare to tackle addiction.Awakn previously announced an...

    2021-04-12 9:54 AM EDT
  • Awakn Acquires Proprietary Next Generation MDMA and Ketamine Data from Prof. David Nutt

    London, United Kingdom--(Newsfile Corp. - March 9, 2021) -  Awakn Life Sciences Inc., a clinical-biotech company researching, developing, and delivering psychedelic medicine to treat addiction and other mental health conditions, today announced the acquisition of significant proprietary research data on next generation candidate MDMA and Ketamine molecules from Prof. David Nutt's Equasy Enterprises. In addition to the acquisition of the data, Prof. Nutt has been appointed as Head of Research to lead Awakn's next generation psychedelic molecule development programme.This latest...

    2021-03-09 7:00 AM EST
  • Awakn Announces Exclusive License Deal with the University of Exeter to Commercialise the 'Ketamine in the Reduction of Alcoholic Relapse' (KARE) Intervention Validated in a Phase II Clinical Trial

    London, United Kingdom--(Newsfile Corp. - March 2, 2021) - Awakn Life Sciences Inc., a clinical-biotech company researching, developing, and delivering psychedelic medicine to treat addiction and other mental health conditions, today announced an exclusive license to use and deliver the 'Ketamine in the Reduction of Alcoholic Relapse' (KARE) psychotherapy intervention, as validated in a Phase II clinical trial led by the University of Exeter.The KARE clinical research study, led by Prof. Celia Morgan of the University of Exeter, was a...

    2021-03-02 7:50 AM EST
  • Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World's First 'MDMA in Alcohol Use Disorder' Clinical Trial

    London, United Kingdom--(Newsfile Corp. - February 19, 2021) - Awakn Life Sciences Inc. announces today the publication of results from its CMO Dr. Ben Sessa's Bristol Imperial MDMA in Alcoholism (BIMA) trial, an open-label safety, tolerability and proof-of-concept study investigating the potential role for MDMA-Assisted Psychotherapy in treating patients with alcohol use disorder (AUD).Results published today in the Journal of Psychopharmacology, show that MDMA-Assisted Psychotherapy (3,4-methylenedioxymethamphetamine) was well tolerated by all participants. No unexpected adverse events were observed, and psychosocial...

    2021-02-19 8:59 AM EST
  • Awakn Appoints James Collins, Ex-Accenture Strategy MD, as Chief Operating Officer

    London, United Kingdom--(Newsfile Corp. - January 25, 2021) - Awakn Life Sciences Inc., a biotechnology company focused on research, development, and delivery of psychedelic medicines for the treatment of mental health conditions, today announced the appointment of James Collins as Chief Operating Officer, effective January 2021.Collins joins from Accenture Strategy where he was a Managing Director (London) for several years, responsible for client relationship development, sales, delivery, and European & Global practise management. He is an industry thought leader with...

    2021-01-25 7:00 AM EST